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Introduction
Acute Respiratory Distress Syndrome 
(ARDS) is a condition characterized by 
damage to the alveoli and cytokine mediated 
inflammation, which results in the disruption 
of the lung endothelium and increased 
pulmonary edema.1 This acute injury can 
result in the onset of hypoxemic respiratory 
failure which eventually manifests itself as 
multiple organ failure, pulmonary fibrosis, 
and pulmonary vascular destruction. 
Common causes include sepsis, aspiration, 
trauma, and pneumonia. The Berlin 
Definition, published in 2012, provides 
updated criteria for diagnosis and disease 
severity stratification.2 For a diagnosis of 
ARDS according to this definition, the 
patient must experience an insulting injury 
or onset of hypoxemia worsening within one 
week, display bilateral opacities upon chest 
imaging, and the pulmonary edema cannot 
be attributed to congestive heart failure. A 
measure of the lung’s ability to transfer 
inhaled oxygen to the blood stream, 
PaO2/FiO2, is used to categorize the severity 
of ARDS, with values of 201-300 termed 
mild, 101-200 moderate, and ≤ 100 severe. 
ARDS affects an estimated 190,000 patients 
annually in the United States, with mortality 
estimates ranging from 26-58%.3-5 
Cisatracurium is an intermediate 
duration, non-depolarizing neuromuscular 
blocking agent (NMBA). It is an isomer of 
atracurium, which antagonizes the action of 
acetylcholine by competitively binding to 
cholinergic receptors on the motor end-plate 
and blocking neuromuscular transmission.6 
Cisatracurium undergoes Hofmann elimin-
ation, or non-enzymatic degradation at 
physiological pH and temperature, to 
inactive metabolites which are eliminated 
primarily by the liver and kidneys. 
Cisatracurium is indicated to relax skeletal 
muscles and facilitate tracheal intubation. It 
also can be used as an adjunct to either 
general anesthesia during surgery or 
sedation during mechanical ventilation in 
the intensive care unit. The two standard 
bolus doses of cisatracurium are 0.15 mg/kg 
and 0.2 mg/kg. This loading dose can be 
followed with a continuous infusion for 
maintenance, with clinical trial doses 
ranging from 0.5-10 mcg/kg/min, and the 
average maintenance dose of 3 mcg/kg/min. 
Three studies, conducted by the same 
research team in France, have evaluated the 
use of cisatracurium in patients with 
ARDS.7-9 The first two trials displayed an 
increase in oxygenation as measured by 
PaO2/FiO2 as well as a reduction in 
inflammatory markers IL-1, IL-6, and IL-8 
associated with cisatracurium use.7-8 These 
two trials indicated a trend toward decreased 
mortality associated with the infusion of 
cisatracurium. However, they did not meet 
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statistical significance and the studies were 
not powered to do so.  
The third trial evaluated 90-day 
mortality associated with a 48-hour 
continuous infusion and found a non-
significant trend toward reduced 90-day 
crude mortality, 31.6% in the cisatracurium 
group vs 40.7% in the placebo group (p = 
0.08).9 However, a statistically significant 
reduction was observed after adjustment for 
baseline PaO2/FiO2, plateau pressure, and 
the Simplified Acute Physiology II score. In 
a subgroup analysis, the more severe 
patients, characterized by a PaO2/FiO2 of 
less than 120, saw the most improvement 
with a statistically significant reduction in 
mortality.9 A meta-analysis and systematic 
review conducted of these three articles 
concluded that compared to placebo, a 48-
hour continuous cisatracurium infusion 
resulted in a statistically significant 28% 
relative risk reduction in hospital 
mortality.10 
 
Case Report 
A 60-year-old Caucasian male was 
brought to the emergency department via 
emergency medical services with a chief 
complaint of abdominal pain beginning 
three hours prior to arrival. Onset was one 
hour post-prandial and rated at 9/10 with no 
associated nausea or vomiting. The patient 
self-reported a history of peptic ulcer at age 
16. He was not taking any prescription 
medications, but reported use of 10 
ibuprofen 200 mg tablets every 2-3 days and 
20-30 aspirin 325 mg tablets a week for 
back pain and "sinus problems". He also 
reported a history of smoking 2-3 cigars per 
day.  
The physical examination was 
remarkable for hypoactive bowel sounds, 
diffuse abdominal tenderness, and guarding. 
An abdominal computed tomography (CT) 
scan revealed pneumoperitoneum consistent 
with perforated viscus. Exploratory 
laparotomy revealed a perforated duodenal 
ulcer which was repaired with a Graham 
patch (Omental patch).  
On post-operative day (POD) 1, the 
patient displayed signs of sepsis (pulse 96, 
respiratory rate 25, white blood cell count 
13.1 K/cm3) and progressive hypoxemia. A 
chest x-ray demonstrated diffuse alveolar 
infiltrates. Attempts at non-invasive positive 
pressure ventilation failed and he was 
intubated subsequently on POD 2. At that 
time, the differential diagnosis included 
congestive heart failure and ARDS 
secondary to sepsis, gastric aspiration, 
and/or pneumonia. Normal echocardiogram 
and serum brain natriuretic peptide (BNP) 
excluded chronic heart failure. As a result, 
lung protective ventilation (tidal volume 6 
mL per kilogram of predicted body weight 
and a plateau pressure of 30 cm of water or 
less) was initiated in accordance with the 
ARDS Network.11 
Despite low tidal volume ventilation and 
empiric broad spectrum antibiotics on POD 
3, the patient had a PaO2/FiO2 of 118, and 
the decision was made to initiate 
neuromuscular blockade to facilitate 
mechanical ventilation and improve 
oxygenation. The patient was sedated with 
midazolam and fentanyl to a Ramsey score 
of 6 and bolused with a 15 mg loading dose 
of cisatracurium, followed by a 37.5 mg per 
hour continuous infusion for 48 hours. Train 
of four (TOF) monitoring was conducted 
intermittently throughout the duration of 
neuromuscular blockade. His doses would 
have been 11.7 mg and 2.3 mg/hr, 
respectively, if the 77.7 kg patient had been 
bolused and a drip started based on the low 
end dosage given in the package insert. 
The infusion was diluted to a 
concentration of 1 mg/mL, resulting in the 
total administration of 1,815 mg of 
cisatracurium in 1,815 mL of 0.9% sodium 
chloride. Five minutes prior to initiation of 
the cisatracurium infusion, a TOF 
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measurement at the wrist revealed 4/4 
twitches. TOF measurements taken 15 
minutes, 30 minutes, one hour, and two 
hours after initiation of the infusion all 
resulted in a TOF of 4/4 twitches. 
Monitoring of TOF’s conducted at 8 hours 
and 18 hours after the initiation of the 
infusion both revealed 0/4 twitches, 
indicating the achievement of 100% 
neuromuscular blockade.  
When it was clear that thorough 
neuromuscular blockade had been achieved, 
TOF measurements were stopped per the 
previous study protocol as well as the lack 
of dosage adjustments. The patient received 
fentanyl and midazolam throughout the 
duration of paralysis. Shortly after 48 hours, 
the cisatracurium infusion was discontinued 
and the patient began to recover full 
neuromuscular function slowly. Within two 
hours, the patient was able to open his eyes 
and follow commands to squeeze an 
examiner’s hand. Roughly seven hours after 
the cessation of the infusion, the patient was 
neurologically intact. Figure 1 highlights the 
observed change in the patients PaO2/FiO2 
associated with the cisatracurium infusion. 
The patient was extubated on POD 9, 
four days after the cessation of the 
cisatracurium infusion. His hospital stay 
subsequently was complicated by 
clostridium difficile infection for which 
treatment with metronidazole was 
administered. The patient was discharged on 
POD 23 to a skilled nursing facility.  
 
 
Figure 1. PaO2/FiO2 ratio. 
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Discussion 
The dose of cisatracurium employed in 
this case was based on that used in the 
Papazian trial: a 15-mg bolus followed by a 
37.5 mg per hour, 48-hour continuous 
infusion.9 As displayed in Figure 1, the 
patient displayed rapid improvements in 
oxygenation corresponding with the 
cisatracurium administration. Improvement 
in the patient’s PaO2/FiO2 of 100 (118 to 
218) from infusion initiation to infusion 
termination were observed. Multiple 
measurements during the infusion also 
displayed even greater improvements in 
oxygenation than the final value obtained, 
with a peak value of 277. The cisatracurium 
infusion appeared to be a turning point 
toward clinical improvement in this patient. 
No other interventions such as prone 
positioning, inhaled nitric oxide, or 
epoprostenol were administered to the 
patient at any point during the treatment 
course. An outlier PaO2/FiO2 value was 
observed the day prior to cisatracurium 
initiation when a weaning trial was 
attempted. The post-cisatracurium period 
also consisted of continued improvement in 
oxygenation, despite the patient’s overall 
complicated clinical picture. 
Train of four monitoring via a peripheral 
nerve stimulator was used throughout the 
48-hour period to assess neuromuscular 
blockade although it was not used to titrate 
the neuromuscular blocking agent. The 
Papazian study did not allow TOF 
monitoring to ensure proper blinding, 
however, in this case it was determined that 
TOF monitoring would be performed to 
assess effectiveness of neuromuscular 
blockade at set dose.9 The patient’s first four 
TOF measurements during the first two 
hours of the infusion displayed 4/4 twitches. 
This was an unexpected observation that is 
not explained readily. The TOF values 
obtained mid-infusion resulting in 0/4 
twitches, suggested that neuromuscular 
blockade was effective. Prolonged blockade 
and muscle weakness are two primary 
concerns associated with NMBA infusion, 
however, this patient displayed no issues 
pertaining to either parameter. The patient 
regained motor function after cessation of 
the infusion and was considered neuro-
logically normal within seven hours. 
In the future, weight-based dosing 
titrated to a train of four response of 0/4 
twitches could be considered to minimize 
cumulative exposure to cisatracurium and 
prevent possible adverse events associated 
with prolonged neuromuscular blockade or 
ICU acquired myopathies or polyneuro-
pathies. Dose reductions could prove to be 
beneficial in terms of cost-savings due to 
medication acquisition costs and medication 
backorders due to drug shortages. To use 
this 77.7 kg patient as an example, his 
dosing range based on the standard 
administration rates would have been 
anywhere from 2.3 mg/hr to 46.6 mg/hr. The 
administered dose of 37.5 mg/hr, while in 
the dosage range, is on the higher end and 
positive outcomes may have been 
achievable with less medication. Diluting 
the concentration of the infusion to 1 mg/mL 
resulted in an increased volume 
administered, however, this was helpful in 
reducing confusion with regards to 
administration rates and dosing. With further 
practice and increased comfort, it may be 
preferable to administer this infusion 
undiluted, given that ARDS is an edematous 
disease state and conservative fluid 
administration is recommended.12 This 
patient displayed a consistently positive 
fluid balance of +2,403 mL on the day of 
initiation, +1,152 mL during the first day, 
and +1,458 mL during the second day. For 
the treatment of this patient, just as in the 
cited studies, cisatracurium was utilized 
exclusively.7-9 Future studies may be 
conducted to determine if the beneficial 
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effects observed are a result of an NMBA 
class effect or are exclusive to 
cisatracurium. 
 
Conclusion 
In summary, this case of a 60-year-old 
Caucasian male with ARDS was treated 
successfully with a 48-hour continuous 
infusion of cisatracurium, resulting in 
oxygenation improvement as measured by 
PaO2/FiO2.  Cisatracurium may have resulted 
in recovery from ARDS and long-term 
survival. Based on these results coupled 
with the available literature, cisatracurium 
appears to be a safe and viable therapeutic 
option for patients with Acute Respiratory 
Distress Syndrome.7-10 
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